Clinical Outcomes of Extended-Release Guanfacine in Adults With Attention-Deficit/Hyperactivity Disorder: A Retrospective Chart Review

Introduction Adult attention-deficit/hyperactivity disorder (ADHD) is a clinically important neurodevelopmental condition with a substantial global prevalence. Extended-release guanfacine (GXR) is a non-stimulant selective α2A-adrenergic receptor agonist approved for adult ADHD in Japan, but real-world adult data remain limited. Materials and methods We conducted a retrospective medical chart review of consecutive eligible adults with ADHD treated with GXR at an ADHD specialty clinic in Japan….

via https://pubmed.ncbi.nlm.nih.gov/42388918/?utm_source=Other&utm_medium=rss&utm_campaign=None&utm_content=1L37KAMf2b_g4WEK3LmdFuKZu9pO3cN7u4ZmO9PPCPeBLMIw1q&fc=None&ff=20260711010904&v=2.20.0